Intended for healthcare professionals


Recent advances: neurology

BMJ 1999; 319 doi: (Published 23 October 1999) Cite this as: BMJ 1999;319:1130

In this paper by A J Larner and S F Farmer (7 August, pp 362-6) the first sentence in the section on multiple sclerosis should have read “Interferon betas (interferon beta-1b, Betaferon; interferon beta-1a, Avonex, Rebif) have been shown to reduce relapse rate in relapsing-remitting multiple sclerosis [not relapsing-remitting (non-progressive) multiple sclerosis] by about one third.14-16


View Abstract